Maher VE, et al. - Experts examined patients who have received anti–programmed death protein 1 or ligand 1 (anti–PD-1/L1) antibodies for the treatment of urothelial cancer, to evaluate the link among tumor response rate, overall survival, and the development of related adverse events of special interest (AESIs) or associated immune-mediated adverse events (imAEs). With 1,747 patients, seven trials, five including patients with prior platinum-based therapy and two trials comprising patients who were cisplatin ineligible, were examined. The chances of reporting a related AESI or related imAE were more among patients who responded to treatment with an anti–PD-1/L1 antibody, this link was not attributable to increased duration of exposure in responding patients. The duration of response was not influenced by systemic corticosteroid use.